TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rates of cytomegalovirus (CMV) viremia and CMV syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: symptom severity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: late-onset adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: complete epithelialisation before day 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wound closure times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wound survival times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression of bcl-2 and bcl-xL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Reported usability of MomsTalkShots
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with vaccine information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Impact on vaccine uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of sessions attended
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Completion rates
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: cough reflex thresholds (C(2) and C(5))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: urge-to-cough log-log slopes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: self-reported improvement in health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Weight of collected secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of overall infections
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first infection
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of osteoarthritis (OA) in the ACL-reconstructed knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compositional changes of cartilage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in WOMAC scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in SF-36 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: incidence of excitement
Endpoint domain: Adverse events/effects
Primary endpoint: mean induction dose of alfaxalone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of animals requiring manual ventilation
Endpoint domain: Adverse events/effects
Primary endpoint: ventilation homogeneity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: global EEL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of adverse maternal events
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of adverse perinatal events
Endpoint domain: Adverse events/effects
Primary endpoint: preterm birth
Endpoint domain: Physiological/clinical
Primary endpoint: Pregnancy rate per IUI cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Area under the ROC curve for PSA to discriminate any prostate cancer vs no cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the ROC curve for PSA to discriminate Gleason grade 7 or greater cancer vs no or lower‐grade cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the ROC curve for PSA to discriminate Gleason grade 8 or greater cancer vs no or lower‐grade cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: incidence of multiorgan failure
Endpoint domain: Mortality/survival
Primary endpoint: mean intensive care unit hospitalization period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-fibre evoked pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: central sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean concentration of anti-HAV antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tolerability of the HAV vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Ve/V(CO2) slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average conversion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in gastrocnemius muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in soleus and peroneal muscle iEMG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Motor Quality Factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hamstrings extensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: throat pain at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: return to normal diet at day 3 and day 7
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: return to normal activities at day 3 and day 7
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: decrease in stress/depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in trauma symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in vigor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain/pressure thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of drivers classified as impaired
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase in SDLP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mania scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vWf concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall improvement on the Brief Psychiatric Rating Scale (BPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for concomitant anticholinergic medication
Endpoint domain: Adverse events/effects
Primary endpoint: Observable akathisia
Endpoint domain: Adverse events/effects
Primary endpoint: Nesfatin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Android fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Volume of new brain lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of patients experiencing new postoperative lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Level of IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: commission errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lane variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speed variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of histologically detected SLNs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of bystander-initiated CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MMN responses to frequency and duration deviants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: word reading score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: comprehensive reading score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement in tender joints counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in swollen joint counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Patient's and physician's assessments
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: LogMAR FVA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blink frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive emotional expression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Negative emotional expression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: visual processing speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced pain disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvements in recreational disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvements in occupational disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: primary bloodstream infections
Endpoint domain: Adverse events/effects
Primary endpoint: local reactions to the dressing
Endpoint domain: Adverse events/effects
Primary endpoint: dressing fixation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Discrimination of chamber pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secondary varus displacement of > 10-degree angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-articular cut out of screws
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of ventilator-associated pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intraoperative cAAI values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time from recovery room to discharge eligibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of eosinophils in nasal lavage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Need for additional medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum P-wave duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stroke/transient ischemic attack
Endpoint domain: Mortality/survival
Primary endpoint: Confirmed or probable AIDS‐defining illness/death
Endpoint domain: Mortality/survival
Primary endpoint: Shade unit reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tooth sensitivity incidence
Endpoint domain: Adverse events/effects
Primary endpoint: dyspnoea rates during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: plasma volume maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safe protein intake to maximize anabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Karnofsky Performance Status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CGI response rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postprandial triglycerides decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Spinal P11 latency reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Late cortical N60-80 latency reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Early cortical P25 amplitude decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean HKA angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean tibial rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean femoral rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the dial test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Knee Documentation Committee knee scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive performance deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean reaction time (MRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Error rate (ER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC0-t and AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TIMI flow better than TIMI-2 after PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of poor myocardial perfusion after PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major adverse cardiovascular events (MACE) within 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Mean duration of the active phase of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mean duration of the second stage of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of cesarean deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Plasma carotenoid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to oral diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to relief of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of CLIDE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dry nights during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KABC cognitive performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: FSR response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurocognitive changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of micturitions/24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: incontinence episodes/24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: volume voided/micturition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: major cardiovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients reaching HbA1c <7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance visual acuity (DVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of supraventricular beats
Endpoint domain: Adverse events/effects
Primary endpoint: Aspirin compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RAIR-induced sphincter relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PAC-SYM symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: TLR4 expression on peripheral blood monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Study retention rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity to detect MCS patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PASI 75 response rates at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation rates due to any reason
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuation rates due to nonmedical reasons
Endpoint domain: Adverse events/effects
Primary endpoint: Meaningful pain relief (mild or no pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal tip rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal tip projection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative reactionary bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of hemodynamic instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: neurocognitive progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: memory and executive function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: time to neurocognitive progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants cured of diarrhoea by 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: MDI technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Environmental control practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum observed DPP-4 inhibition effect (Emax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean alogliptin peak plasma concentrations (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to return to SBP >80 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thigh muscle perimeter at 10cm from the patella
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: SDQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute peripheral neuro-sensory toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Recommendation of experimental drug as treatment of choice
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Presumptive eradication rates for Streptococcus pneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diarrhea as a treatment-associated adverse reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to infant antiretroviral prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of major complications after system upgrade
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in lipid and protein oxidation products
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increment of total antioxidant capacity of plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increment of total plasmatic thiol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal distance between the CS and MVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: blood levels of t‐tau
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: vascular vasomotion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: MISI value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disposition index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Symptoms of hypogonadism
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion achieving BP goal by Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fMRI response to cocaine cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of Variation (CV) for flexibility measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SANS total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPRS total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal reductions in viral levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severe grade adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Concordance rate of DUS-CEMRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-Tg levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cardiac rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BCVA gains over 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient preference for pazopanib over sunitinib
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life